Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

Completed · Phase 1

Conditions studied: Bipolar I Disorder, Schizophrenia

In brief

This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.

Key facts

Study ID

NCT04127058

Run by

Vanda Pharmaceuticals

People needed

12

Starts

2019-10-07

Expected to finish

2019-11-27

Last updated by the study team

2020-04-13

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients 18 to 65 years of age (inclusive)
• Diagnosed with either schizophrenia or bipolar I disorder, manic or mixed type as per DSM-V criteria
• Symptomatically stable within the past two months

You may not qualify if…

• Exposure to any investigational medication, including placebo, in the past 60 days
• Non-response to clozapine

Where it is running

• Vanda Investigational Site — Marlton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.